论文部分内容阅读
目的:比较CAP方案经支气管动脉灌注与外周静脉用药治疗非小细胞肺癌的疗效。方法:45例患者随机分为A、B两组,均用CAP方案治疗,A组经支气管动脉灌注用药,B组经外周静脉用药,均治疗3个疗程。结果:A组CR14.3％,PR57.1％,B组CR为0,PR 37.5％。毒副反应:A组的Ⅱ～Ⅲ度骨髓抑制及消化道反应均低于B组(P<0.05)。结论:CAP方案治疗非小细胞肺癌经支气管动脉灌注疗效优于经外周静脉用药,且毒副反应较轻。
OBJECTIVE: To compare the efficacy of CAP regimen with bronchial artery infusion and peripheral intravenous drug in the treatment of non-small cell lung cancer. Methods: Forty-five patients were randomly divided into A and B groups, all of whom were treated with CAP regimen. A group was given bronchial artery infusion and B group was treated by peripheral vein. All of them were treated for 3 courses. Results: A group CR14.3%, PR57.1%, B group CR was 0, PR 37.5%. Toxicity and side effects: The bone marrow suppression and digestive tract reaction of Ⅱ ~ Ⅲ degree in group A were lower than those in group B (P <0.05). CONCLUSION: The CAP regimen is superior to transcatheter arterial infusion in the treatment of non-small cell lung cancer through peripheral bronchial artery with less toxic and side effects.